The One Skin OS1 product is a something they are calling a senolytic peptide. I heard in interviews with the founder that they went with peptides so they could avoid the long and expensive process of FDA approval that they’d incur if they went for a drug solution. But, it seems there are likely many drugs on the market that may already be available and that are senolytic compounds that are available but not yet used in skin creams (or are generic and therefore nobody will ever fund the trials to see if they work as skin creams).
Here is some more research I’ve come across regarding senolytics like dasatinib and skin aging. I have not yet found any research papers (that I can access) where they’ve tested the most tested senolytic drugs in any topical formulations… e.g. Dasatinib, Quercetin, Fisetin and Navitoclax. Seems like something that would not be very hard to try in a formulation. Ideally pre and post tested with something like the Visia skin scanner as I described here.
Background
Skin ageing is caused by numerous factors that result in structural and functional changes in cutaneous components. Research has shown that senescent cells are known to accumulate in skin ageing, however, the role of senescent cells in skin ageing has not been defined.
Objectives
To elucidate the role of the senescent cell in skin ageing, we evaluated the effect of known senolytic drugs on senescent dermal fibroblasts.
Conclusions
Taken together, our results indicate that selective clearance of senescent skin cells can attenuate and improve skin ageing phenotypes and that senolytic drugs may be of potential use as new therapeutic agents for treating ageing of the skin.
Attenuation of intrinsic ageing of the skin via elimination of senescent dermal fibroblasts with senolytic drugs
https://onlinelibrary.wiley.com/doi/abs/10.1111/jdv.18051
Advancements in therapeutic drugs targeting of senescence
https://journals.sagepub.com/doi/full/10.1177/2040622320964125